Company
Eli Lilly and Co
NYSE:LLY
Eli Lilly and Co is engaged in drug manufacturing businesses. The company discovers, develops, manufactures and markets products in the human pharmaceutical products segment.
147 stories · page 5 of 8
Eli Lilly stock starts on front foot after rival Alzheimer trial fails
Roche has missed a US$10 billion a year opportunity, leaving less competition for rival treatments in development
Eli Lilly shares fall after fake verified account tweets 'insulin is free now'
The parody account had purchased a verified checkmark with Twitter blue, making it difficult to distinguish from the real thing
Eli Lilly wins US$375mln US government order for COVID-19 drug
The drug can help stop those with only mild to moderate symptoms from becoming dangerously ill, believes the company
Eli Lilly says baricitinib cuts COVID-19 recovery time if used with Gilead Inc’s remdesivir
The rheumatoid arthritis treatment was shown to speed up recovery by one day
Eli Lilly and Co unveils cheaper version of popular insulin injection Humalog
Mark Emalfarb, CEO of the biopharmaceutical group Dyadic, calls the move 'a very good first step'
Investments and investor services
LATE MOVERS: Chipotle gains after 4Q earnings and revenue beat estimates of analysts
Also moving were General Motors and Take-Two Interactive Software
Investments and investor services
Late Movers: Salesforce.com Inc rallies after announcing plans to add 1,500 jobs in Ireland
Also moving were Caterpillar and Boeing, as well as Tesla and Eli Lilly
Eli Lilly’s $8B bet on Loxo is a ‘vote of confidence’ for novel scientific approaches that use DNA to treat cancer
Genprex Inc CEO Rodney Varner said the deal was ‘further validation’ of the promise of cancer therapies that target specific cancer-causing genetic abnormalities
Archive
EARLY MOVERS - Loxo Oncology shares skyrocket on news of Eli Lilly acquisition; DXC Technology to buy Luxoft Holding
Also in the frame in pre-market is electric car titan Tesla and media group CBS Corp
Eli Lilly tops 3Q earnings and revenue forecasts while lifting guidance; shares climb
Stronger revenue was driven by new medicines and prudent expense management
Dicerna Pharmaceuticals shares surge after $100M research deal with Eli Lilly
The biotech has received a $100 million upfront payment to continue its development of cardio-metabolic disease, neurodegeneration and pain treatments
Eli Lilly raises full-year earnings guidance; flags plans to float Elanco Animal Health
"Lilly delivered strong results once more in the second quarter in terms of operational performance, pipeline advancements and strategic objectives," said David Ricks, the company's chairman and CEO.